Compare NTCT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTCT | STOK |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 1999 | 2019 |
| Metric | NTCT | STOK |
|---|---|---|
| Price | $29.59 | $31.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $31.00 | ★ $34.50 |
| AVG Volume (30 Days) | 486.9K | ★ 592.7K |
| Earning Date | 02-05-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.32 | 0.68 |
| Revenue | ★ $861,434,000.00 | $205,632,000.00 |
| Revenue This Year | $5.90 | $428.87 |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ $22.49 | $46.60 |
| Revenue Growth | 4.91 | ★ 1128.17 |
| 52 Week Low | $18.12 | $5.35 |
| 52 Week High | $30.67 | $38.69 |
| Indicator | NTCT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 64.53 | 52.53 |
| Support Level | $27.80 | $30.75 |
| Resistance Level | $28.72 | $33.28 |
| Average True Range (ATR) | 0.99 | 2.13 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 98.91 | 52.59 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.